Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
75,916,643
Share change
+4,299,320
Total reported value
$1,165,169,505
Put/Call ratio
4.9%
Price per share
$15.35
Number of holders
138
Value change
+$49,763,836
Number of buys
91
Number of sells
47

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q1 2023

As of 31 Mar 2023, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 138 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 75,916,643 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, RA CAPITAL MANAGEMENT, L.P., RTW INVESTMENTS, LP, BlackRock Inc., FMR LLC, COWEN AND COMPANY, LLC, STATE STREET CORP, VANGUARD GROUP INC, Cormorant Asset Management, LP, and Avoro Capital Advisors LLC. This page lists 138 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.